<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214759</url>
  </required_header>
  <id_info>
    <org_study_id>UT-NPEP</org_study_id>
    <nct_id>NCT01214759</nct_id>
  </id_info>
  <brief_title>Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)</brief_title>
  <official_title>A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of the combination of truvada and
      raltegravir given for 28 days for the prevention of HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-Occupational Post-Exposure Prophylaxis (nPEP) after sexual exposure to HIV is recommended
      by the Centers for Disease Control (CDC). Although no efficacy data exist for Post-Exposure
      Prophylaxis (PEP) after sexual exposure, PEP has been shown to reduce HIV transmission in
      other exposure situations such as occupational exposures and mother-to-child transmission.
      The role in nPEP of the newer agents approved for the treatment of HIV infection remains
      unknown. The anti-HIV drug raltegravir works early in the life cycle of the virus, before it
      integrates with human DNA. It has few side effects and drug interactions what makes it an
      ideal drug for an nPEP regimen.

      We aim to asses the safety and tolerability of the combination of truvada and raltegravir for
      nPEP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>This measure assesses whether the combination of Truvada and Raltegravir prevents the acquisition of HIV at six months among HIV-negative people who have been exposed to HIV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Exhibiting Clinical or Laboratory Abnormalities Resulting From the 28-day Exposure to the Antiretroviral Drugs Being Explored in This Study</measure>
    <time_frame>28 days</time_frame>
    <description>Participants who experienced side effects categorized as grade 3 or higher by the Division of AIDS table for grading the severity of adult and pediatric adverse events were tested for clinical or laboratory abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Assessed by the Number of Participants Who Completed the 28-day Course of the Antiretroviral Drugs Being Explored in This Study</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Truvada and Raltegravir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Tenofovir 200mg/emtricitabine 300mg once a day</description>
    <arm_group_label>Truvada and Raltegravir</arm_group_label>
    <other_name>Tenofovir 200mg/emtricitabine 300mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir 400mg twice a day</description>
    <arm_group_label>Truvada and Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 18 years of age

          -  HIV uninfected on the basis of a negative HIV rapid test, EIA or Western blot, and
             without any signs or symptoms of acute HIV infection

          -  Able to understand and provide consent

          -  High-Risk Exposure Characteristic (One or more of the below, unprotected or with
             failed condom use):

               -  Receptive Anal Intercourse

               -  Insertive Anal Intercourse

               -  Receptive Vaginal Intercourse

               -  Insertive Vaginal Intercourse

               -  Receptive Oral Intercourse with Intraoral Ejaculation with known HIV+ source

          -  High-Risk Source (One or more of the below):

               -  Known HIV positive

               -  MSM

               -  MSM/W

               -  CSW

          -  Sexual perpetrator Partner of one of the above

          -  Exposure within 72 hours of presentation

          -  Not known to be HIV-1 positive

          -  No countermanding concomitant medications or allergies

        Exclusion Criteria:

          -  Patients &lt;18 years of age

          -  Unable to understand and provide consent

          -  Non-occupational exposure to HIV-1 not recent enough to commence the first dose of
             study medication within 72 hours from the exposure

          -  Known to be HIV positive

          -  Any condition which in the opinion of the intake provider will seriously compromise
             the patient's ability to comply with the protocol, including adherence to nPEP
             medication

          -  Demonstrated HIV-1 positive on rapid testing

          -  Unwillingness to commit to barrier-method (male and/or female condom) use until HIV
             negative status is confirmed 6 months after exposure

          -  Unwillingness of breast-feeding women to transition to formula feeding

          -  Any active psychiatric illness or active drug or alcohol abuse that, in the opinion of
             the investigator, could prevent compliance with study procedures

          -  Pregnancy

          -  Chronic hepatitis B infection, diagnosed by either positive serum HBsAg or positive
             serum HBV DNA; or prior lamivudine or other therapy for hepatitis B

          -  Creatinine clearance less than 30 mL/min as calculated by Cockcroft-Gault formula

          -  Unwillingness to participate in study procedures, including Mental Health referral and
             intervention

          -  Known intolerance or allergy to tenofovir DF, emtricitabine or raltegravir

          -  Use of prohibited concomitant medication: dilantin, phenobarbital and rifampin which
             cannot be used with raltegravir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen J Vigil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, Cheever L, Johnson M, Paxton LA, Onorato IM, Greenberg AE; U.S. Department of Health and Human Services. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005 Jan 21;54(RR-2):1-20.</citation>
    <PMID>15660015</PMID>
  </reference>
  <reference>
    <citation>Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS. 2004 Oct 21;18(15):2065-73.</citation>
    <PMID>15577628</PMID>
  </reference>
  <reference>
    <citation>Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney M, Chambers D, Franses K, Coates TJ, Katz MH. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis. 2001 Mar 1;183(5):707-14. Epub 2001 Feb 1.</citation>
    <PMID>11181146</PMID>
  </reference>
  <reference>
    <citation>Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benveniste RE, Black R. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995 Nov 17;270(5239):1197-9.</citation>
    <PMID>7502044</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <results_first_submitted>January 7, 2016</results_first_submitted>
  <results_first_submitted_qc>January 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2016</results_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Karen Vigil</investigator_full_name>
    <investigator_title>Assistant Professor - Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>prevention</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Truvada</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Truvada and Raltegravir</title>
          <description>Single arm
Truvada: Tenofovir 200mg/emtricitabine 300mg once a day
Raltegravir: Raltegravir 400mg twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>28 Days nPEP Completion</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All who were enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Truvada and Raltegravir</title>
          <description>Single arm
Truvada: Tenofovir 200mg/emtricitabine 300mg once a day
Raltegravir: Raltegravir 400mg twice a day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months</title>
        <description>This measure assesses whether the combination of Truvada and Raltegravir prevents the acquisition of HIV at six months among HIV-negative people who have been exposed to HIV.</description>
        <time_frame>6 months</time_frame>
        <population>All who completed all study visits</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada and Raltegravir</title>
            <description>Single arm
Truvada: Tenofovir 200mg/emtricitabine 300mg once a day
Raltegravir: Raltegravir 400mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months</title>
          <description>This measure assesses whether the combination of Truvada and Raltegravir prevents the acquisition of HIV at six months among HIV-negative people who have been exposed to HIV.</description>
          <population>All who completed all study visits</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Exhibiting Clinical or Laboratory Abnormalities Resulting From the 28-day Exposure to the Antiretroviral Drugs Being Explored in This Study</title>
        <description>Participants who experienced side effects categorized as grade 3 or higher by the Division of AIDS table for grading the severity of adult and pediatric adverse events were tested for clinical or laboratory abnormalities.</description>
        <time_frame>28 days</time_frame>
        <population>Only participants who experienced side effects categorized as grade 3 or higher by the Division of AIDS table were tested for clinical or laboratory abnormalities, and since no participants experienced side effects greater than grade 1, no participants were tested for clinical or laboratory abnormalities.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada and Raltegravir</title>
            <description>Single arm
Truvada: Tenofovir 200mg/emtricitabine 300mg once a day
Raltegravir: Raltegravir 400mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Exhibiting Clinical or Laboratory Abnormalities Resulting From the 28-day Exposure to the Antiretroviral Drugs Being Explored in This Study</title>
          <description>Participants who experienced side effects categorized as grade 3 or higher by the Division of AIDS table for grading the severity of adult and pediatric adverse events were tested for clinical or laboratory abnormalities.</description>
          <population>Only participants who experienced side effects categorized as grade 3 or higher by the Division of AIDS table were tested for clinical or laboratory abnormalities, and since no participants experienced side effects greater than grade 1, no participants were tested for clinical or laboratory abnormalities.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Assessed by the Number of Participants Who Completed the 28-day Course of the Antiretroviral Drugs Being Explored in This Study</title>
        <time_frame>28 days</time_frame>
        <population>All who were enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada and Raltegravir</title>
            <description>Single arm
Truvada: Tenofovir 200mg/emtricitabine 300mg once a day
Raltegravir: Raltegravir 400mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Assessed by the Number of Participants Who Completed the 28-day Course of the Antiretroviral Drugs Being Explored in This Study</title>
          <population>All who were enrolled</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were assessed at follow up visits at 2 weeks, 4 weeks, 3 months, and 6 months.</time_frame>
      <desc>All adverse events that occurred are categorized as grade 1 (mild) by the Division of AIDS table for grading the severity of adult and pediatric adverse events. No grade 2 (moderate), grade 3 (severe), or grade 4 (potentially life threatening) adverse events occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>Truvada and Raltegravir</title>
          <description>Single arm
Truvada: Tenofovir 200mg/emtricitabine 300mg once a day
Raltegravir: Raltegravir 400mg twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Face pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Delayed menstruation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a pilot study with a small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Karen Vigil</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>(713) 500-6703</phone>
      <email>Karen.J.Vigil@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

